Jazz Pharmaceuticals plc Income (Loss) from Continuing Operations before Income Taxes, Domestic
Jazz Pharmaceuticals plc (JAZZ) reported Income (Loss) from Continuing Operations before Income Taxes, Domestic of $164.70 million for the 12-month period ending 2025-12-31, per its 10-K filed 2026-02-24.
Financial Statements › Income Statement
us-gaap:IncomeLossFromContinuingOperationsBeforeIncomeTaxesDomestic · last filed 2026-02-24
- Jazz Pharmaceuticals plc income (loss) from continuing operations before income taxes, domestic for fiscal 2025 was $164.70M, a 66.92% decline from fiscal 2024.
- Jazz Pharmaceuticals plc income (loss) from continuing operations before income taxes, domestic for fiscal 2024 was $497.86M, a 10.83% increase from fiscal 2023.
- Jazz Pharmaceuticals plc income (loss) from continuing operations before income taxes, domestic for fiscal 2023 was $449.21M.
- Jazz Pharmaceuticals plc income (loss) from continuing operations before income taxes, domestic for fiscal 2022 was -$50.31M, a 151.57% decline from fiscal 2021.
| Period end | Income (Loss) from Continuing Operations before Income Taxes, Domestic 12 month |
|---|---|
| 2025-12-31 | $164.70M 10-K · filed 2026-02-24 |
| 2024-12-31 | $497.86M 10-K · filed 2026-02-24 |
| 2023-12-31 | $449.21M 10-K · filed 2026-02-24 |
| 2022-12-31 | -$50.31M 10-K · filed 2025-02-26 |
| 2021-12-31 | $97.56M 10-K · filed 2024-02-28 |
| 2020-12-31 | -$102.33M 10-K · filed 2023-03-01 |
| 2019-12-31 | -$6.45M 10-K · filed 2022-03-01 |
| 2018-12-31 | $170.67M 10-K · filed 2021-02-23 |
| 2017-12-31 | $77.48M 10-K · filed 2020-02-25 |
| 2016-12-31 | $179.57M 10-K · filed 2019-02-26 |
| 2015-12-31 | $233.78M 10-K · filed 2018-02-27 |
| 2014-12-31 | $238.35M 10-K · filed 2017-02-28 |
| 2013-12-31 | $186.90M 10-K · filed 2016-02-23 |
| 2012-12-31 | -$73.95M 10-K · filed 2015-02-24 |
| 2011-12-31 | $0.00 10-K · filed 2014-02-25 |
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| Summit Therapeutics Inc. (SMMT) | United States | $13.071B | -13.21 |
| BridgeBio Pharma, Inc. (BBIO) | United States | $12.947B | -20.72 |
| CORCEPT THERAPEUTICS INC (CORT) | United States | $12.804B | 169.10 |
| BIOMARIN PHARMACEUTICAL INC (BMRN) | United States | $11.879B | 151.80 |
| MADRIGAL PHARMACEUTICALS, INC. (MDGL) | United States | $11.859B | -38.17 |
| Elanco Animal Health Inc (ELAN) | United States | $11.177B | -61.80 |
| Viatris Inc (VTRS) | United States | $20.008B | -0.00 |
| UNITED THERAPEUTICS Corp (UTHR) | United States | $20.249B | 17.64 |
| Axsome Therapeutics, Inc. (AXSM) | United States | $10.274B | -66.82 |
| ARROWHEAD PHARMACEUTICALS, INC. (ARWR) | United States | $9.331B | -42.28 |